- Tumors1000+
- Pathologic Processes1000+
- Pathology1000+
- Cancer1000+
- Nervous System Diseases932
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Pathologic Processes1000+
- Pathology1000+
- Cancer1000+
- Nervous System Diseases932
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- ER positive
- PD-L1 positive
- HER2 positive
- PR positive
- PD-L1 negative
- PR negative
- EGFR negative
- EGFR positive
- ER negative
- KRAS positive
- ALK negative
- BRAF positive
- CD20 positive
- BRCA1 positive
- BRCA2 positive
- p16 positive
- HLA-A positive
- ALK positive
- BRAF negative
- HLA positive
- MYC positive
- CD19 positive
- IDH positive
- MET positive
- ROS1 negative
- HLA negative
- HR positive
- IDH negative
- CD5 positive
- PIK3CA positive
- RET positive
- TP53 positive
- BCL2 positive
- HLA-A negative
- p16 negative
- MET negative
- PALB2 positive
- ROS1 positive
- BCL6 positive
- KRAS negative
- NRAS positive
- CCND1 positive
- FLT3 positive
- HPV positive
- MSI-H positive
- RB1 positive
- TP53 negative
- ANA positive
- BCR-ABL1 positive
- MSS positive
- NF1 positive
- RB1 negative
- dMMR positive
- Anti-dsDNA positive
- BRCA positive
- Ex19del positive
- HBsAg positive
- HPV negative
- L858R positive
- MMR positive
- RAS positive
- RET negative
- ctDNA positive
- BRCA1 negative
- CD4 positive
- FGFR2 positive
- MGMT negative
- NRAS negative
- NTRK positive
- SMN1 positive
- BRCA2 negative
- CD19 negative
- CD20 negative
- CD30 positive
- CFTR positive
- CLDN18.2 positive
- COL7A1 positive
- FLT3 negative
- MDM2 positive
- MGMT positive
- MLH1 positive
- MMR negative
- MSH2 positive
- MSH6 positive
- MSI positive
- MSI-H negative
- NTRK negative
- PMS2 positive
- PTEN positive
- RAS negative
- RF positive
- TTR positive
- dMMR negative
- p53 positive
- ABCA4 positive
- ARID1A positive
- ATM positive
- FGFR3 positive
- FMR1 positive
- GRN positive
- HBV DNA negative
- HBV DNA positive
- Ki-67 positive
- NF2 positive
- SMN2 positive
- T790M positive
- TROP2 negative
- TROP2 positive
- pMMR positive
- t(11;14) positive
- 1p negative
- APP positive
- BRCA negative
- BRIP1 positive
- C5 positive
- C9orf72 positive
- CD23 positive
- CD3 positive
- CDK12 positive
- CHEK2 positive
- DLL3 positive
- DMPK positive
- EBV positive
- EPCAM positive
- FANCA positive
- FGFR positive
- FVIII positive
- HR negative
- HRD positive
- JAK2 positive
- Ki67 positive
- MSI negative
- NTRK1 positive
- PH positive
- PSEN1 positive
- PSEN2 positive
- Philadelphia Chromosome positive
- Philadelphia chromosome negative
- RAD51 positive
- RAF positive
- RHO positive
- TMB positive
- anti-Ro autoantibodies positive
- anti-Ro/SSA positive
- anti-Sm positive
- anti-Smith positive
- t(11;14)(q13;q32) positive
- β-thalassemia positive
- 11q negative
- 11q positive
- 19q negative
- AChR positive
- AKT negative
- ALPL positive
- ALT positive
- APOL1 positive
- Aβ1-42 positive
- BAP1 positive
- BARD1 positive
- BCR-ABL positive
- CD123 positive
- CD1a positive
- CD2 positive
- CD22 negative
- CD30 negative
- CD34 positive
- CD5 negative
- CD7 positive
- CD8 positive
- CD99 positive
- CDK4 positive
- CEACAM5 positive
- CHEK1 positive
- COL1A1 positive
- COL1A2 positive
- CRLF2 positive
- DGM7 positive
- DMD positive
- Del(17p) negative
- ER/PR positive
- FANCL positive
- FAP positive
- FGFR1 positive
- FOXO1 fusion negative
- G719X positive
- GBA positive
- GLA positive
- HBB positive
- HBsAg negative
- HCG positive
- HEXA positive
- HEXB positive
- HPV16 positive
- HRAS positive
- HRRm positive
- HbE positive
- HbSS positive
- IDS positive
- IGHV negative
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1 Prior Chemotherapy Regimen for Metastatic Disease
- 1927nm Fractional Thulium Laser Treatment
- ALK TKI Therapy
- Abrocitinib
- Activating EGFR mutation [exon 19 deletion or exon 21 (L858R) substitution mutation]
- Active Treatment for Cutaneous Squamous Cell Carcinoma
- Active Treatment for Non-Invasive Basal Cell Carcinoma
- Adjuvant Radiation for 4-6 weeks
- Adjuvant Therapy (except reconstruction)
- Adjuvant or Neoadjuvant Chemotherapy with Metastatic Disease Development within 6 Months
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
6682 trials
1
2
3
…50